Effect of Pyridostigmine Bromide on Serum Bromide Concentration and the Anion Gap

Victor Faradji-Hazan, M.D., James R. Oster, M.D.,2 Daniel G. Federman, M.D., Anthony R. Clerch, M.D., and Guido O. Perez, M.D.

METHODS

We obtained approximately 30 mL of venous blood from 15 patients (one previously reported [4]) already taking pyridostigmine Br. None had clinical evidence of Br toxicity. Fourteen had myasthenia gravis; one had the Eaton-Lambert syndrome. Thirteen were outpatients; two were hospitalized—both for decompensation of their myasthenic state. The patients' data are compared with those of 18 normal controls not taking any medications whose serum Br levels were within the normal range. All sera were analyzed for Na, Cl, HCO3, K, and creatinine (Cr) with a Kodak Ektachem 700 automated analyzer (Eastman Kodak Co.) [5]. Na, Cl, HCO3, and K were also determined with a Beckman Synchron CX3 analyzer (Beckman Instruments, Inc.) [6]. Serum Br was measured by the trichloroacetic acid method [7,8], which detects Br concentrations as low as 10 μg/mL (0.125 mmol/L). With it, the serum Br level in normal individuals is less than 30 μg/mL (0.375 mmol/L) [9].

The Ektachem 700 measures Cl and HCO3 (total CO2 content) by using simultaneous deposition of 10 μL of sample on separate halves of a multilayered "dry slide" [5]. The methodology differs for each assay: Cl-ISE (potentiometry) and HCO3-ISE (membrane sensitive to carbonate ion) [5]. The Synchron CX3 measures Cl with a two-phase Ag/AgCl ISE and measures HCO3 by the differential pH rate of change for CO2 employing both measuring and reference pH electrodes [6]. Statistical analysis was carried out by one-way analysis of variance followed by the Newman-Keuls multiple range test (with P set at 0.05) [9]. We also used the Bonferroni method [10], wherein dividing the P value (t test) usually required for significance (0.05) by the number of potential comparisons gives the new P value necessary to achieve statistical significance.

RESULTS AND DISCUSSION

The mean age of the 15 patients, 59 ± 3 (SE) years, was greater (P < 0.001) than that of the 18 control subjects (30 ± 1 years). The average daily dose of pyridostigmine Br was 362 ± 48 mg (4.4 ± 0.6 mg/kg body wt). According to the manufacturer, the average daily dosage of the medication is 600 mg, with a maximum of 1,500 mg. The period over which the patients had been taking a constant dosage varied widely and averaged 43 ± 9 months.
When measured with the Kodak Ektachem 700, the serum Cl was significantly higher than that obtained with the Beckman Synchron CX3 analyzer (Table 1). The anion gap was strikingly lower with the Ektachem 700 (4.4 ± 1.2 mmol/L) than with the Synchron CX3 analyzer (12.3 ± 0.6 mmol/L). The average serum Br was 1.9 ± 0.5 mmol/L, with individual values ranging from 0.3 to 8.1 mmol/L. Nine values were equal to or exceeded 1.0 mmol/L; five of these had corresponding anion gap levels of 3 mmol/L or less. There was a strong negative correlation between the serum Br and the anion gap (r = -0.91; P < 0.001), but there was no significant relationship between serum Br and either the dosage or duration of use of pyridostigmine Br.

The average serum Br of the controls (0.2 ± 0.02 mmol/L) was almost 10-fold lower than that of the patients (P < 0.001), and there were no significant differences between the serum values for Cl or anion gap determined on the Ektachem 700 versus the Synchron CX3 analyzer. There were no significant differences between patients and controls in serum Cr.

Although the in vitro addition of pyridostigmine Br to serum is known to raise serum Cl artifactually (11), interference with Cl measurements by pyridostigmine Br ingestion has, to our knowledge, been reported in only three patients (4,12,13)—two of whom were taking large doses of the medication (in one instance resulting in frank bromism).

In the presence of Br, Cl determination with ISE results in major positive interference. With the Ektachem 700, serum Cl may increase by approximately 3 mmol/L for each 1-mmol/L increase in serum Br (5). In addition, the CO₂ content may increase by approximately 2 mmol/L for each 1-mmol/L increase in serum Br (5). In this present study, the small increase in serum HCO₃ was not statistically significant. On the other hand, Br is not cited as an interfering substance for CO₂ content determination in the Synchron CX3 manual (6).

There were no significant electrolyte or anion gap differences in the control group between the values obtained with the two analyzers, suggesting that, in the patient group, the Ektachem 700 data were faulty. Both of the automated analyzers used in the study presented here employ ISE for the measurement of Cl; nevertheless, the Cl levels differed considerably in the patient group as measured by the two instruments. Of note, Nagamine et al. (3) state that the degree of interference by Br with Cl determination may vary among different instruments with the same assay principle—particularly with ISE technology.

Myasthenia gravis is an uncommon but not rare disease whose estimated prevalence in the United States is between 43 and 84 per million (i.e., a total of up to approximately 21,000 patients) (14). Because a majority of the known patients are probably using pyridostigmine Br, the phenomenon described herein

**TABLE 1. Serum electrolyte and anion gap data in patients receiving pyridostigmine Br and in control subjects**

<table>
<thead>
<tr>
<th></th>
<th>Na</th>
<th>K</th>
<th>Cl (mmol/L)</th>
<th>HCO₃</th>
<th>AG</th>
<th>Cr (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients (N = 15)</strong> (serum Br&lt;sub&gt;a&lt;/sub&gt; 1.9 ± 0.5 mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kodak Ektachem 700</td>
<td>141.1 ± 0.7</td>
<td>4.1 ± 0.1</td>
<td>106.1 ± 1.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>30.5 ± 0.8</td>
<td>4.4 ± 1.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>80.2 ± 5.7</td>
</tr>
<tr>
<td>P value</td>
<td>NS</td>
<td>NS</td>
<td>&lt;0.0025</td>
<td>NS</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Beckman Synchron CX3</td>
<td>142.7 ± 0.7</td>
<td>4.2 ± 0.1</td>
<td>101.5 ± 0.8</td>
<td>28.9 ± 0.5</td>
<td>12.3 ± 0.6</td>
<td></td>
</tr>
<tr>
<td><strong>Control Subjects (N = 18)</strong> (serum Br 0.2 ± 0.02 mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kodak Ektachem 700</td>
<td>141.8 ± 0.4</td>
<td>4.0 ± 0.1</td>
<td>101.5 ± 0.5</td>
<td>28.4 ± 0.7</td>
<td>11.9 ± 0.7</td>
<td>89.4 ± 4.3</td>
</tr>
<tr>
<td>P value</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Beckman Synchron CX3</td>
<td>143.0 ± 0.5</td>
<td>4.2 ± 0.1</td>
<td>101.8 ± 0.5</td>
<td>29.7 ± 0.6</td>
<td>11.4 ± 0.5</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Data are means ± SE; NS, not significant (P ≥ 0.05); AG, anion gap.
<sup>b</sup> P < 0.001 versus controls.
<sup>c</sup> P < 0.001 versus Ektachem controls.
<sup>d</sup> P < 0.001 versus Synchron controls.

Except for serum Br (two comparisons), all P values shown relate to six potential comparisons between four groups.
is important. Clinicians should also be aware that a considerable number of other medications available in the United States contain Br (13).

In conclusion, routine therapeutic doses of pyridostigmine bromide may, in the absence of clinical bromism, induce methodology-dependent artifactual increases in serum Cl (and sometimes HCO₃⁻) with a consequent marked reduction of the anion gap. This may be particularly confusing in the diagnostic evaluation of acutely ill patients admitted to an intensive care unit.

ACKNOWLEDGMENTS
We thank Ms. Michelle R. Pierce for preparation of the manuscript; Mr. Michael Cohn, Laboratory Service, for his assistance; Drs. William Sheremata and Robert Shebert for referral of their patients; Ms. Lottie Cason for performing the statistical analyses; and Dr. Lawrence M. Fishman for his helpful suggestions.

REFERENCES